Discovery of Potent and Selective G9a Degraders for the Treatment of Pancreatic Cancer
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01192 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Yunkai Shi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu C…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Histone-Lysine N-Methyltransferase, Antineoplastic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai Municipality, Taishan Scholar Foundation of Shandong Province, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
G9a, which was initially identified as a histone H3 Lys9 (H3K9) methyltransferase, is potentially an attractive therapeutic target for human cancers. Despite its importance, there is no available selective G9a chemical probe because its homologous protein GLP shares approximately 80% of its sequence with G9a. The development of G9a chemical probes with high selectivity for G9a over GLP is a big challenge but is extremely valuable for understanding G9a-related biology. Herein, we developed a first-in-class selective G9a degrader G9D-4, which induced a dose- and time-dependent G9a degradation without degradation of GLP. G9D-4 exhibited effective antiproliferative activities in a panel of pancreatic cancer cell lines and was able to sensitize KRASG12D mutant pancreatic cancer cells to KRASG12D inhibitor MRTX1133. These data clearly demonstrated the practicality and importance of a selective G9a degrader as a preliminary chemical probe suitable for understanding G9a-related biology and a promising strategy for the treatment of pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China.
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
- University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 100049, China.
- Division of Antitumor Pharmacology, State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China.
Förderung
- Natural Science Foundation of Shanghai Municipality
- Taishan Scholar Foundation of Shandong Province
- Science and Technology Commission of Shanghai Municipality
- Natural Science Foundation of Shandong Province
- Shandong Laboratory Program
Zitieren
APA
Shi, Y., Shen, Q., Long, R., Mao, Y., Tong, S., Yang, Y., Gao, J., Zhou, H., Chen, Y., & Zhou, B. (2024). Discovery of Potent and Selective G9a Degraders for the Treatment of Pancreatic Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01192
Vancouver
Shi Y, Shen Q, Long R, Mao Y, Tong S, Yang Y, et al. Discovery of Potent and Selective G9a Degraders for the Treatment of Pancreatic Cancer. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01192
BibTeX
@article{Shi2024,
author = {Shi, Yunkai and Shen, Qianqian and Long, Ruikai and Mao, Yiwen and Tong, Shuaihang and Yang, Yaxi and Gao, Jing and Zhou, Hu and Chen, Yi and Zhou, Bing},
title = {Discovery of Potent and Selective G9a Degraders for the Treatment of Pancreatic Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01192}
}
EUVIMED